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The evolutionarily conserved protein kinase p38 mediates
innate resistance to environmental stress and microbial infec-
tion. Four p38 isoforms exist in mammals and may have been
co-opted for new roles in adaptive immunity. Murine T cells
deficient in p38, the ubiquitously expressed p38 isoform,
showed no readily apparent cell-autonomous defects while
expressing elevated amounts of another isoform, p38. Mice
with T cells simultaneously lacking p38 and p38 displayed
lymphoid atrophy and elevated Foxp3 regulatory T cell fre-
quencies. Double deficiency of p38 and p38 in naïve CD4 T
cells resulted in an attenuation of MAPK-activated protein
kinase (MK)-dependent mTOR signaling after T cell receptor
engagement, and enhanced their differentiation into regulatory
T cells under appropriate inducing conditions. Pharmacological
inhibition of the p38-MK-mTOR signaling module produced
similar effects, revealing potential for therapeutic applications.
The T cell receptor (TCR)3 and receptors for costimulatory
molecules and cytokines deliver key signals for the develop-
ment and function of T cells. Upon ligand binding, these recep-
tors trigger intracellular signaling cascades that are integrated
to elicit changes in gene expression and cellular phenotype. In
peripheral naïve T cells, for example, antigen encounter and
costimulation in conjunction with exposure to specific cyto-
kines lead to the induction of a gene transcription program that
specifies differentiation into a functionally distinct subset of
effector, memory, or regulatory cells. The magnitude as well
as the nature of receptor-initiated signals contributes to
determining the fate and functional capabilities of activated
T cells. Modulating intracellular signaling in T cells by phar-
macological means can dampen, augment, or re-route im-
mune responses, an approach that may be harnessed to sup-
press immune-mediated disorders and enhance antitumor
immunity.
Homologues of p38, a MAPK family member, are found in
organisms ranging from yeast to humans. In single-celled life,
p38 is activated upon stress and damage, and signals to evoke
cell-autonomous mechanisms for adaptation, repair, and sur-
vival (1, 2). The role of p38 signaling in multicellular organisms
extends to antimicrobial defense, with p38-dependent phos-
phorylation events at work downstream of receptors for
immune signals (3–5). Inmost physiological contexts, p38 acti-
vation in mammalian cells occurs through a “classical” MAPK
cascade, in which p38 is phosphorylated by the MAPK kinases
MKK3 andMKK6, which themselves are activated by stimulus-
specific MAPK kinase kinase-mediated phosphorylation (6).
Four mammalian p38 isoforms (p38, p38, p38, and p38)
have evolved to assume specialized but partly redundant phys-
iological roles. Of particular importance to immune function is
p38, the isoform most widely expressed in tissues (7, 8) and
involved in cell responses to cytokines and microbial products
(9–11). Moreover, p38 was originally identified as the molec-
ular target of a class of small-molecule anti-inflammatory com-
pounds (12), and since this initial finding p38 has been impli-
cated in signaling processes associatedwith a host of diseases of
inflammatory etiology (6). Cell type-specific loss of p38 signal-
ing in mice, with p38 gene ablation restricted to epithelial
cells, myeloid cells, or dendritic cells, was found to prevent or
ameliorate inflammatory responses and pathology in ultravio-
let radiation-induced dermatitis (13, 14), chemically induced
colitis (15), contact hypersensitivity reactions (16), and experi-
mental autoimmune encephalomyelitis (17).
The activation of p38 in T cells occurs not only through the
classical MKK3/6-mediated process (18–20) but also via an
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alternative pathway involving p38 phosphorylation by the
TCR-proximal tyrosine kinase ZAP70 (21). ZAP70-activated
p38 and p38 serve some redundant functions in T cells (22),
and their activating phosphorylation sites and substrate speci-
ficities differ from those of MKK3/6-activated counterparts
(23). Several studies examined the in vivo effects of impaired
p38 function in T cells by using pharmacological p38 inhibitors
(24, 25), dominant-negative p38 and MKK transgenes (19,
24–27), p38- andMKK-null alleles (18, 28–30), and p38 gene
knock-in alleles selectively precluding alternative activation
(22, 31, 32). The findings from these approaches suggested a
role for T cell p38 signaling in thymocyte development, TCR-
induced proliferation and apoptosis, IFN-, IL-2, and IL-17A
production, and autoimmune diseases such as collagen-in-
duced arthritis and experimental autoimmune encephalomy-
elitis. Other studies that examined mice with T cells lacking
p38 alone or both p38 and p38, however, did not observe
substantial effects on IFN- and IL-17A production or experi-
mental autoimmune encephalomyelitis (17). The role of p38
signaling inT cells, therefore, remains debatable, its potential as
a target for anti-inflammatory therapy yet to be definitely
appraised.
In this study, we find as-yet-unreported effects of ablating
p38 and p38 in T cells: mice with T cells simultaneously
deficient in the two p38 isoforms exhibit enhanced regulatoryT
(Treg) cell induction and attenuated allergic inflammation
when challenged with epicutaneous antigen. In vitro differenti-
ation experiments confirm the role of p38 signaling in limiting
Treg cell induction, and identify how p38 and p38 cooperate
to perform this role. Our findings suggest inhibition of p38
signaling as a novel means to promote Treg cell generation and
treat immune-mediated diseases.
Results
Development and Maintenance of T Cells Lacking p38 and
p38—We previously reported that mice with T cell-specific
ablation of p38 (Mapk14fl/fl-LckCre; ) showed moderate
lymphoid atrophy, and had decreased proportions of CD8
subsets among lymph node and splenic T cells (16). Combined,
these changes translated to a decline in the absolute number of
CD8 T cells available for antigen-specific immune responses
such as contact hypersensitivity reactions. Nevertheless, T cells
from these mice, taken individually, remained functionally
competent throughout the immune response: in hapten-ex-
posed animals, p38-deficient T cells were efficiently primed to
become cytokine-producing effector cells, and formed a
memory population that could transfer hapten sensitivity to
naïve mice (16). This may be due either to a lack of critical
cell-autonomous functions of p38 in T cells during immune
responses or to functional compensation by other p38 iso-
forms. Such functional redundancy has been documented
for p38 and p38 in various cell types including T cells (22,
33). Of note, p38 expression in mice was prominent in T
cells compared with other cell types (Fig. 1A), and further
elevated in lymph node and splenic T cells with p38 abla-
tion (Fig. 1B).
To examine whether p38 and p38 exert redundant func-
tions in T cells, we crossed  mice with p38-null mice
(Mapk11/; ) to generate mice with T cells lacking both
p38 and p38 (Mapk14fl/fl-LckCre-Mapk11/; ). T cells
frommice did not express detectable amounts of both p38
isoforms (Fig. 1C). The size and cellularity of the thymus, lymph
nodes, and spleen of mice decreased compared with those
of wild-type (WT) mice (Fig. 1,D and E). The lymphoid tissues
of  and  mice tended to be atrophic too, but to lesser
extents than counterparts. Single and double deficiency of
p38 and p38 in T cells did not prevent the thymic develop-
ment of CD4 and CD8 T cells or their homing to and main-
tenance in the lymph nodes and spleen (Fig. 1F). In keeping
with our previous report (16), the proportions of lymph node
and splenic CD8 T cells were lower in  mice than in WT
mice, but not further reduced by the additional loss of p38 in
mice (Fig. 1F).
Signaling by p38 and p38 in T Cells—We examined the
effects of p38 deficiency on TCR-induced intracellular signal-
ing in naïve CD4 T cells. Compared with T cells lacking only
either isoform, T cells from  mice exhibited a more com-
plete abrogation of p38 phosphorylation after treatment with
TCR agonists, anti-CD3 and anti-CD28 antibodies (Fig. 2, A
and B). Loss of p38 has been shown to potentiate signaling by
other MAPK family members, ERK and JNK, in a multitude of
cell types (34). Correspondingly,  T cells showed increased
phosphorylation, and thus activation, of ERK and JNK upon
TCR stimulation (Fig. 2A). We observed that MAPK-activated
protein kinase (MK) 2, a protein kinase immediately down-
stream of p38, was constitutively phosphorylated in cultured T
cells independently of TCR stimulation. Nevertheless, MK2
phosphorylation was abolished in  T cells, but not  and
 T cells (Fig. 2, A and B), suggesting that p38 was indispens-
able for steady-state phosphorylation of MK2.
Some previous studies suggested a connection between the
p38-MK2 signaling module and the mechanistic target of rapa-
mycin (mTOR): p38 was required for stress-induced mTOR
signaling in arsenite-exposed fibroblasts, hypoxic-reoxygen-
ated cardiomyocytes, and anisomycin-treated macrophages
(35–37). Anisomycin-induced mTOR activation has been
attributed to the ability ofMK2 to phosphorylate and inactivate
the mTOR inhibitor TSC2 (37, 38). It remained unexplored,
however, whether signaling events consistent with this
model occurred in T cells during TCR activation. We found
that the loss of MK2 activation in  T cells was accompa-
nied by a marked reduction in the phosphorylation of TSC2
at serine-1254, which is associated with MK2-dependent
inactivation (Fig. 2A). In parallel, mTOR pathway activation,
as indicated by S6K and S6 phosphorylation, was greatly
weakened in  T cells but persisted in  and  T cells,
albeit in lower magnitudes than in WT counterparts (Fig. 2,
A and B). TCR-induced S6 phosphorylation was also dimin-
ished in CD4 T cells lacking MK2 and the related protein
kinase MK3 (Fig. 3, A–E), which served overlapping signal-
ing functions (39, 40). Intriguingly, TCR-induced S6 phos-
phorylation remained intact in CD8 T cells lacking MK2
and MK3 (Fig. 3, F and G). In summary, p38-dependent acti-
vation and regulation of intracellular signaling events in
naïve CD4 T cells were abolished by ablation of both p38
and p38 but not either alone.
p38/-MK2/3-mTOR Signaling in T Cells
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Activation and Th Effector Differentiation of T Cells Lacking
p38 and p38—We sought to identify functional defects in
T cells that resulted from loss of p38 signaling. First, we
isolated total (CD3) splenic T cells fromWT and mice
and stimulated them with anti-CD3 and anti-CD28 antibod-
ies. The proliferation rate of TCR-stimulated CD4 T cells
was substantially reduced by p38 and p38 deficiency (Fig.
4A). These effects could indicate a cell-autonomous role for
p38 signaling in TCR-induced proliferation or, alternatively,
a contribution of a non-cell-autonomous mechanism that
suppressed T cell activation more effectively without the p38
isoforms. Treg cells, contained in the total splenic T cell
preparations, might exert the suppressive effect under the
latter scenario.
To exclude or minimize the possible influence of Treg cells,
we performed subsequent experiments using cell preparations
devoid of antigen-experienced T cells including Foxp3 cells.
To this end, the CD4CD62L subset was purified from sple-
nic T cells and subjected to TCR stimulation. Naïve T cells thus
prepared from  mice proliferated at only moderately
reduced rates (Fig. 4B) compared with the effects seen with
total splenic T cells. Naïve CD4 T cells from WT and 
mice produced comparable amounts of IFN-, IL-13, and
IL-17A upon TCR stimulation (Fig. 4C), and differentiated into
FIGURE 1.Mice with p38 and p38 deficiency in T cells display lymphoid atrophy and a decreased proportion of lymph node and splenic CD8
T cells. A, whole cell lysates from epithelial cells (E), fibroblasts (F), macrophages (M), dendritic cells (D), and T cells (T) were analyzed by immunoblotting.
The cells were isolated from the small intestine (SI), colon (Cl), skin (Sk), lymph node (LN), thymus (Th), and spleen (Sp) of themouse, or derived by in vitro
differentiation of progenitors in the mouse bone marrow (BM). B and C, whole cell lysates from T cells (T) of the indicated mouse tissues and from liver
tissue (Lv) were analyzed by immunoblotting. D and E, indicated mouse tissues (n  3, each group) were photographed (D), and their cell numbers
were determined (E). Cell numbers shown as mean  S.D. (n  3, each group). **, p  0.01. F, percentage of CD4 and CD8 cells in the indicated
mouse tissues was determined by flow cytometry. Data are representative of two (A–C) or three (D and E) experiments and of six animals (F) with similar
results.
p38/-MK2/3-mTOR Signaling in T Cells
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the effector cell subsets specialized for producing these cyto-
kines (Th1, Th2, and Th17) with similar efficiencies (Fig. 4, D
and E). Therefore, p38 signaling in T cells seemed largely dis-
pensable for TCR-driven activation and differentiation toward
Th effector cells.
Treg Differentiation of T Cells Lacking p38 and p38—We
examined whether p38 signaling played a role in the induction
of Treg cells. Upon TCR stimulation in conjunction with expo-
sure to TGF-, naïve CD4 T cells from  mice differenti-
ated intoTreg cellsmore efficiently thanWTcounterparts (Fig.
5, A and B). Consistently, T cells from  mice produced
greater amounts of Foxp3 mRNA and protein than WT cells
during the course of Treg cell induction (Fig. 5,C andD). TCR-
responsive Foxp3 mRNA induction in the absence of a Treg-
skewing condition was also higher in naïve CD4 T cells
from  mice (Fig. 5C), suggesting that p38 signaling
served to limit Foxp3 expression even before the Treg phe-
notype was established. The suppressive function of Treg
cells from  mice, as determined by the ability to inhibit
TCR-induced proliferation of naïve CD4T cells, was intact,
and in fact slightly enhanced compared with that ofWTTreg
cells (Fig. 5E).
We next investigated Treg cell formation in vivo. Notably,
mice in a steady-state condition exhibited a small but con-
sistent increase in Treg cell frequency: CD4 T cells from the
thymus and spleen of  mice contained elevated Foxp3
fractions (Fig. 5, F andG). To examine Treg cell induction dur-
ing T cell-mediated immune responses, we subjected WT and
 mice to an experimental condition that elicited contact
hypersensitivity reactions. In this model of allergic dermatitis,
epicutaneous exposure to a small-molecule antigen or hapten
establishes T cell immunity and, upon re-encounter with the
hapten, induces T cell-mediated inflammation accompanied
by skin rashes and swelling.  mice displayed greatly
attenuated responses to the hapten 2,4-dinitrofluoroben-
zene (DNFB; Fig. 5H) and, simultaneously, a massive expan-
sion of the Treg cell compartment in the skin-draining
lymph node (Fig. 5, I and J).
Given the observations described above, p38 signaling was
not essential for T cell development and steady-state main-
tenance. Nevertheless, p38 deficiency in T cells produced
perceptible effects in  mice—altered sizes of CD8 and
CD4Foxp3 T cell subpopulations. It was conceivable that
these effects resulted from impaired p38 signaling in cell types
other than T cells, as  mice had systemic p38 deficiency.
To address this possibility, we examined the lymphoid tissues of
RAG1-deficient mice that were sublethally irradiated and
engrafted with bone marrow from  mice. These radiation
chimeras, in which deficiency of not only p38 but also p38
was restricted to lymphocytes, exhibited decreased CD8 and
increased CD4Foxp3 T cell subsets compared with control
chimeras engrafted with WT bone marrow (Fig. 6, A and B).
Hence, the changes in the frequency of T cell subsets in 
mice were likely attributable to the loss of cell-autonomous p38
function. The influence of Cre recombinase-mediated toxicity,
if any, was also ruled out based on the normal ranges of CD8
and CD4Foxp3 T cell abundance in LckCre mice (Fig. 6, C
and D).
Role of p38/-MK2/3-mTOR Signaling in Treg Cell In-
duction—Our analysis of  mice revealed novel effects of
loss of p38 signaling in CD4 T cells: increased Foxp3 expres-
sion and enhanced induction of fully functional Treg cells. We
sought to identify the molecular mechanism whereby p38 sig-
naling modulated Treg cell induction, and explored the possi-
ble involvement of the protein kinases whose activation was
regulated by or dependent on p38. Excessive activation of
ERK and JNK, seen in TCR-stimulated  T cells (Fig. 2, A
and B), might contribute to enhancing Treg cell induction;
we refuted this possibility, however, as pharmacological
inhibition of their activation did not significantly reduce the
efficiency of Treg cell induction from  T cells (Fig. 7A).
Further, deficiency of mitogen- and stress-activated kinase
(MSK) 1 and MSK2, which are phosphorylated by and relay
FIGURE 2. p38 and p38 cooperate to shape TCR-induced intracellular
signaling inCD4Tcells.AandB, naïveCD4T cells fromthe indicatedmice
were left unstimulated or stimulated with anti-CD3 and anti-CD28. Whole
cell lysates were prepared after the indicated durations of stimulation and
analyzed by immunoblotting (A). Solid bars on the right indicate bands
corresponding to multiple protein isoforms detected by the antibodies.
p-, phosphorylated. Immunoblot signals were quantified by densitome-
try, and the relative signal intensities (the indicated proteins relative to
actin) are shown (B). Data are representative of three experiments with
similar results (A and B).
p38/-MK2/3-mTOR Signaling in T Cells
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signals from ERK and p38 (6), did not profoundly affect Treg
cell induction (Fig. 7B).
As shown above, S6 protein phosphorylation, an event
downstream of mTOR activation, was induced in WT CD4
T cells upon TCR stimulation but substantially diminished
in  and MK2/3-double knock-out (DKO) counterparts
(Fig. 2, A and B; and Fig. 3, A–E). We therefore explored
MK2/3 and mTOR as possible links for p38-dependent mod-
ulation of Treg cell induction. Indeed, pharmacological inhi-
bition and genetic ablation of mTOR have been shown to
enhance Foxp3 expression in CD4 T cells, and promote
their differentiation into Treg cells (41, 42), paralleling the
effect of loss of p38 signaling. To verify the role of p38/-
MK2/3-mTOR signaling in regulating Treg cell induction,
we tested small-molecule compounds acting on distinct
points of this protein kinase cascade: SC409, PF3644022, and
rapamycin. These compounds, inhibiting p38, MK2, and
mTOR, respectively, suppressed TCR-induced S6 phosphor-
ylation as did genetic ablation of p38 (Fig. 7, C and D). Fur-
ther, these compounds augmented in vitro Treg cell induc-
tion to similar extents (Fig. 7E).
To obtain genetic evidence forMK2/3-dependent regulation
of Treg cell induction, we investigated T cells isolated from
MK2/3-DKO mice. Double deficiency of MK2 and MK3 in
mice did not perturb the development and maintenance of
CD4 and CD8 T cells (Fig. 8A). We compared the relative
fitness ofWT andMK2/3-DKOT cells in Treg cell formation
in vitro by mixing equal numbers of naïve CD4 T cells from
WT CD45.1 mice and MK2/3-DKO CD45.2 mice and
subjecting them to a Treg-skewing condition. The contribu-
tion of CD45.2 cells to the Treg cell pools obtained at day 5
was greater than that of CD45.1 cells (Fig. 8, B and C). The
efficiency of naïve-to-Treg conversion was also significantly
higher with MK2/3-DKO T cells (Fig. 8D). In addition, sim-
FIGURE 3.MK2/3 signaling promotes TCR-induced mTOR pathway activation in CD4 T cells. A–C, naïve CD4 T cells from the indicated mice were
left unstimulated or stimulatedwith anti-CD3 and anti-CD28. Whole cell lysates were prepared after the indicated durations of stimulation and analyzed
by immunoblotting (A). p-, phosphorylated. Immunoblots were scanned and shown in histograms (B). Immunoblot signals were quantified by densi-
tometry, and the relative signal intensities (p-S6 relative to GAPDH) are shown (C).D–G, splenocytes from the indicatedmice were treated with anti-CD3
for the indicated durations. Relative p-S6 amounts in CD4 and CD8 cells were analyzed by flow cytometry (D and F). The percentage of p-S6 cells
among CD4 and CD8 cells were analyzed by flow cytometry, and is shown as mean  S.D. (n  3, each group; E and G). MFI, mean fluorescence
intensity. *, p 0.05; **, p 0.01. Data are from one experiment (A–C) or representative of three animals with similar results (D–G).
p38/-MK2/3-mTOR Signaling in T Cells
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ilar to  mice, MK2/3-DKO mice exhibited a subtle but
significant increase in steady-state Treg cell frequency in the
spleen (Fig. 8, E and F). In summary, our findings point to the
p38/-MK2/3-mTOR cascade as a new actionable target
for promoting the induction of immunosuppressive Treg
cells.
Discussion
A role for the p38 signaling pathway in immune responses
was suspected early on, and the promise of effectively treating
immune-mediated diseases by suppressing this pathway has
been driving efforts to understand how this pathway contrib-
utes to immunity and inflammation. The findings of this study
suggest a role for p38 signaling in several aspects of T cell biol-
ogy: mice with T cell-restricted ablation of p38 and p38
expression exhibited reduced numbers of T cells and increased
frequencies of Treg cells in lymphoid tissues. The decreases in
contact hypersensitivity reactions in these mice were likely
attributable to either or both of these two effects. From an
extensive investigation of protein kinases activated down-
stream of the TCR, we identified the p38/-MK2/3-mTOR
cascade as a key signaling module regulating Treg cell induc-
tion while ruling out the involvement of ERK, JNK, andMSK.
Pharmacological agents interfering with this multilayered
protein kinase module may improve the efficiency of gener-
ating or expanding Treg cells ex vivo for adoptive cell trans-
fer therapy.
TCR and cytokine receptors play key roles in Treg cell devel-
opment and function, transmitting intracellular signals that are
integrated to induce Foxp3 expression in naïve CD4 T cells
and stabilize it in Treg-committed cells. Cytokines provide
major cues for the skewing of CD4 T cell differentiation, but
the strength of TCR signaling also contributes to determining
the fate of activated T cells and, in particular, the efficiency of
Treg cell formation (43, 44). Signaling by p38 may be pivotal to
interpreting the intensity of TCR activation and tuning Treg
signature expression accordingly. We have demonstrated that
the loss of p38 signaling in T cells is associated with enhanced
Treg cell induction. This effect is in accord with the require-
ment for p38 in TCR-inducedmTOR activation.While we note
FIGURE 4. T cells lacking p38 andp38 remain capable of TCR-induced activation anddifferentiation into cytokine-producing effector cells in vitro.
A and B, splenic T cells (A) and naïve CD4 T cells (B) from the indicated mice were labeled with CFSE and stimulated with anti-CD3 and anti-CD28. After 72 h
of stimulation, cell proliferationwas analyzedbydetermining thepercentageof cellswith CFSEdilution amongCD4 cells by flow cytometry. Thepercentages
of divided cells are shown asmean S.D. (n 3, each group).C, naïve CD4 T cells from the indicatedmicewere left unstimulated or stimulatedwith anti-CD3
and anti-CD28 (CD3/28). After 48 h of stimulation, IFN-, IL-13, and IL-17A amounts in the culture supernatants were determined by ELISA, and are shown as
mean S.D. (n 2 for IFN- and IL-13, each group; n 3 for IL-17A, each group). D and E, naïve CD4 T cells from the indicated mice were stimulated with
anti-CD3, anti-CD28, and simultaneously treatedwith varying agents for 5 days to induce Th1 (top), Th2 (middle), and Th17 (bottom) cell differentiation. Effector
T cell differentiation was analyzed by determining the percentage of cells with the indicated intracellular cytokines by flow cytometry. Cell percentages are
shown as mean S.D. (n 3, each group). Data are from one experiment (A–E).
p38/-MK2/3-mTOR Signaling in T Cells
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MK2/3-mediated phosphorylation of TSC2 as a potential
mechanistic link between p38 andmTOR, it is also possible that
MK2/3 may act on a signaling event upstream of TSC2 as the
two MKs have been found to affect Toll-like receptor-induced
production of phosphatidylinositol 3,4,5-trisphosphate, a
phospholipid activator of AKT-mTOR signaling (45). Of note,
there were earlier reports of Treg cell induction enhanced by
genetic ablation of other protein kinases downstream of TCR, as
seen with T cells lacking the TEC family kinase ITK or doubly
deficient for the MAPK kinase kinases MEKK2 and MEKK3 (20,
46). Intriguingly, TCR-induced p38 and mTOR activation was
impaired in theseTcells (20, 46, 47). It remains to be seenwhether
thep38-MK2/3-mTORmodule serves as anodal point of intracel-
lular signaling inTcellswhere upstream inputs are integrated into
a scalable signal for Foxp3-driven Treg cell induction.
Experimental Procedures
Animals— (Mapk14fl/fl-LckCre),  (Mapk11/), and
MAPK-activated protein kinase (MK) 2/3-double knock-out
(DKO) mice were previously described (16, 40, 48). 
FIGURE 5.Deficiency of p38 and p38 in T cells leads to increased Treg cell induction. A and B, naïve CD4 T cells from the indicatedmicewere cultured
in the presence of anti-CD3, anti-CD28, IL-2, TGF-, anti-IFN-, and anti-IL-4 for 5 days, and analyzed for CD25 and Foxp3 expression by flow cytometry. Values
connected with dotted line indicate cell percentages from the same experiment (B). **, p 0.01 (the paired Student’s t test). C, naïve CD4 T cells from the
indicated mice were left unstimulated, stimulated with anti-CD3 and anti-CD28 (CD3/28) alone, or stimulated with CD3/28 in conjunction with treatment
with IL-2, TGF-, anti-IFN-, and anti-IL-4 (Treg mix). After 72 h of treatment, total RNA was isolated, and Foxp3 expression was analyzed by quantitative
real-time PCR (n 2).D, naïve CD4 T cells from the indicatedmicewere stimulatedwithCD3/28 in conjunctionwith treatmentwith the Tregmix.Whole cell
lysates were prepared at the indicated time points, and Foxp3 protein was analyzed by immunoblotting. E, CFSE-labeled naïve CD4 T cells were treatedwith
anti-CD3 and anti-CD28 in the absence (Teff alone) and presence of Treg cells from WT and  mice at the indicated ratios (Teff/Treg). After 3 days of
stimulation, cell proliferation was analyzed by determining the percentage of cells with CFSE dilution by flow cytometry. Relative proliferation is shown as
mean  S.D. (n  3, each group). F and G, percentage of CD25Foxp3 cells among CD4 cells in the indicated mouse tissues was determined by flow
cytometry (F) and shown as mean S.E. (n 7, each group; G). *, p 0.05; **, p 0.01. H–J, indicated mice were sensitized and challenged with the hapten
DNFB. Hapten-specific skin swelling was determined at the indicated time points after challenge and shown as mean  S.D. (n  4, each group; H). The
percentage of CD25Foxp3 cells among CD4 cells in the draining lymph nodes of the indicatedmice was determined by flow cytometry 72 h after hapten
challenge (I) and shownasmean S.E. (n 6, eachgroup; J). *,p 0.05. Data are representative of five (A andB), two (C andD), or three experiments (E–G) with
similar results, or from one experiment (H–J).
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(Mapk14fl/fl-LckCre-Mapk11/) mice were generated by
crossing  and  mice. All mice were on a C57BL/6 back-
ground. Contact hypersensitivity to DNFB was induced as
described (16). For bone marrow engraftment, 8-week-old
Rag1/mice (The Jackson Laboratory) were sublethally irra-
diated (450 rads), engrafted with bone marrow cells (4  106)
fromWTandmice, andmaintained on sulfamethoxazole-
and trimethoprim-supplemented drinking water for 8 weeks
prior to analysis. All animal experimentswere conducted under
IACUC-approved protocols.
Reagents—DNFB, brefeldin A, and PF3644022 were from
Sigma-Aldrich; SC409, PD98059, SP600125, and rapamycin
from EMD Millipore; CFSE from Life Technologies; IFN-,
IL-2, IL-4, IL-6, and TGF- from Peprotech. Fluorescent-con-
jugated antibodies against the following markers were used in
flow cytometry: CD3 (145–2C11), CD4 (GK1.5 and RM4–5),
CD8 (53–6.7), CD25 (PC61.5), Foxp3 (anti-mouse/rat staining
kit), IFN- (XMG1.2), IL-4 (BVD6–24G2), IL-17A (eBio17B7;
all from eBioscience). Antibodies against the following proteins
were used in cell stimulation, Fc receptor blocking, and cyto-
kine neutralization: CD3 (145–2C11), CD28 (37.51), IFN-
(XMG1.2), IL-12 (C17.8), IL-4 (11B11), CD16/CD32 (2.4G2; all
from BD Pharmingen); and hamster IgG (MP Biomedicals).
Antibodies against the following proteins were used in immu-
noblotting: ERK (9102), phosphorylated (p-) p38 (9211), p-JNK
(9251), p-ERK (9101), p-S6K1 (9205), p-S6 (4858), p-MK2
(3007), p-TSC2 (3616; all from Cell Signaling Technology);
p38 (sc-535; Santa Cruz Biotechnology); p38 (33–8700; Life
Technologies); p38 and p38 (University of Dundee); JNK
(554285, BD Pharmingen); Foxp3 (14–5773, eBioscience); and
actin (A4700; Sigma-Aldrich).
TCell Isolation andFlowCytometry—CD3Tcells andnaïve
CD4T cells were isolated from the thymus, lymph nodes, and
spleen of 6–8-week-old mice using the Pan T cell Isolation Kit
and the CD4CD62LTCell Isolation Kit, respectively (Milte-
nyi Biotec). Single-cell suspensions obtained from mice were
FIGURE 6. The T cell-related phenotype ofmice is not attributable to p38 function in the non-lymphoid compartment or Cre recombinase
toxicity. A and B, Rag1/micewere sublethally irradiated and engraftedwith bonemarrow fromWT andmice. The percentage of CD4 and CD8
cells among CD3 cells (A) and CD25Foxp3 cells among CD4 cells (B) in the indicatedmouse tissues was determined by flow cytometry 8weeks after
bonemarrow transfer. C andD, percentage of CD4 and CD8 cells among CD3 cells (C) and CD25Foxp3 cells among CD4 cells (D) in the indicated
mouse tissues was determined by flow cytometry. Data are representative of two (A and B) or three (C and D) animals per group.
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incubated with Fc receptor-blocking anti-CD16/CD32, stained
with fluorescent-conjugated antibodies, and analyzed by flow
cytometry using FACSCanto and LSRFortessa (BD Biosci-
ences) and FlowJo software (Tree Star).
T Cell Activation in Vitro—Naïve CD4 T cells from the
spleen were stimulated with plate-bound anti-CD3 (10 g/ml)
and soluble anti-CD28 (2g/ml). Carboxyfluorescein diacetate
succinimidyl ester (CFSE)-labeled T cells were stimulated with
anti-CD3 and anti-CD28 for 3 days, and analyzed by flow
cytometry. To analyze Treg suppressive function, lymph node
and splenic CD4CD25 cells were isolated using the Regula-
tory T Cell Isolation Kit (Miltenyi Biotec). CFSE-labeled naïve
CD4 T cells were mixed with CD4CD25 cells, stimulated
with anti-CD3 and anti-CD28 for 3 days, and analyzed for
proliferation.
T Cell Differentiation in Vitro—To induce T cell differentia-
tion into Th effector cells, naïve CD4 T cells from the spleen
were incubated with the following agents: Th1, IL-2 (20 ng/ml),
IL-12 (10 ng/ml), IFN- (10 ng/ml), anti-IL-4 (10 g/ml); Th2,
IL-2 (20 ng/ml), IL-4 (10 ng/ml), anti-IFN- (10 g/ml), and
anti-IL-12 (10 g/ml); and Th17, IL-6 (20 ng/ml), TGF- (2.5
ng/ml), anti-IFN- (2g/ml), anti-IL-4 (2g/ml), soluble anti-
CD28 (1 g/ml), soluble anti-CD3 (0.25 g/ml), and plate-
bound anti-hamster IgG (0.12 g/ml). After 5 days of differen-
tiation, cells were treated with phorbol myristate acetate (50
ng/ml) and ionomycin (1M) in the presence of brefeldin A (10
g/ml) for 5 h and analyzed by flow cytometry. For Treg cell
induction, naïve CD4 T cells were stimulated with anti-CD3
FIGURE7.Thep38/-MK2/3-mTORsignalingmodule regulatesTregcell
induction. A and B, naïve CD4 T cells from the indicatedmicewere cultured
in a Treg-skewing condition for 5days as in Fig. 5A. The cellswere treatedwith
vehicle (DMSO), PD98059 (PD), and SP600125 (SP) throughout the culture
period (A) or without any of these compounds (B). CD25 and Foxp3 expres-
sion was analyzed by flow cytometry. C and D, naïve CD4 T cells from the
indicated mice were left unstimulated or stimulated with anti-CD3 and anti-
CD28. The cellswere left untreated (C) or treatedwith vehicle (DMSO), thep38
inhibitor SC409 (SC), the MK2 inhibitor PF3644022 (PF), and rapamycin (Rm)
1 h before stimulation (D). Whole cell lysates were prepared after the indi-
cated durations of stimulation and analyzed by immunoblotting. p-, phos-
phorylated. E, naïve CD4 T cells were cultured in a Treg-skewing condition
for 5 days as in Fig. 5A in the presence of the indicated agents throughout the
culture period. CD25 and Foxp3 expression was analyzed by flow cytometry.
Data are representative of two (A and E) or three experiments (B–D) with
similar results.
FIGURE 8. Genetic ablation of MK2 and MK3 expression leads to en-
hanced Treg cell induction. A, percentage of CD4 and CD8 cells in the
indicatedmouse tissueswas determined by flow cytometry. B–D, equal num-
bers of naïve CD4 T cells from WT (CD45.1) and MK2/3-DKO (CD45.2) mice
were mixed and analyzed before (day 0) and 5 days after culture in a Treg-
skewing condition as in Fig. 5A. Thepercentageof CD45.1 andCD45.2 cells
(B and C) and CD25Foxp3 cells among TCRCD4 cells (D) was deter-
mined by flow cytometry. Cell percentages are shown asmean S.D. (n 4,
each group). *, p 0.05; ***, p 0.001. E and F, percentage of CD25Foxp3
cells amongTCRCD4 cells in the indicatedmouse tissueswasdetermined
by flow cytometry (E) and shown as mean S.D. (n 7, each group; F). ***,
p 0.001. Data are representative of two (A) or four (B–D) experiments with
similar results or from one experiment (E and F).
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and anti-CD28 in the presence of IL-2 (20 ng/ml), TGF- (5
ng/ml), anti-IFN- (10 g/ml), and anti-IL-4 (10 g/ml) for 5
days. Cells were treated with SC409 (10 M), PF3644022 (10
M), and rapamycin (0.1 M) where indicated.
Protein and RNAAnalysis—Whole cell lysates were prepared
and analyzed by immunoblotting as described (49). Immuno-
blot signals were quantified by using ImageJ software (National
Institutes of Health). Cytokine concentrations in culture super-
natants were measured by ELISA. Real-time quantitative PCR
was performed using gene-specific primers.
Statistical Analysis—Data values are expressed as mean 
S.E. or mean S.D. p values were obtained with the unpaired,
two-tailed Student’s t test unless otherwise indicated.
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